TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nursing home operators say GLP-1 medications are increasingly common among new residents and are being used for conditions beyond diabetes and weight management. Care teams are adapting monitoring and nutrition practices, while reimbursement remains unsettled: a Medicare bridge program runs through 2027, but a more permanent plan has been delayed.
GLP-1 medications are becoming more common among nursing home residents, with operators reporting that many new admissions already take the drugs for diabetes, weight management and other chronic conditions. The wider use is prompting facilities to expand clinical monitoring and staff education, while uncertain coverage and out-of-pocket costs leave residents and providers weighing who will pay.
At Venza Care, about 30% to 40% of newly admitted residents are taking a GLP-1, chief nursing officer Lisa Chubb told Skilled Nursing News. She said the proportion is higher at facilities with more short-stay residents. Chubb described use as broadening from diabetes and weight loss to what clinicians see as preventive use related to cardiovascular conditions, metabolic health and organ health.
Venza has added weekly “nutrition at risk” meetings and electronic health record assessments to help interdisciplinary teams document medication reviews, provide education and monitor weight loss. Registered dietitians are involved in care for residents on the drugs, Chubb said. The aim is to weigh potential health benefits against concerns that excessive weight loss could worsen muscle weakness or frailty.
Payment depends in part on a resident’s coverage and prescription. Jessie McGill, a senior curriculum development specialist at the American Association for Post-Acute Care Nursing, said a Medicare Part D bridge program covers certain GLP-1s prescribed for weight loss, with a $50 monthly fee in addition to Part D coverage. The program is limited to Wegovy, Zepbound and Foundeo, according to McGill. Residents who cannot afford the fee may still face a barrier, including people who have both Medicare and Medicaid.
For residents covered under Medicare Part A, the nursing home may have to absorb the medication cost, McGill said. A prescription outside the bridge program can represent a substantial expense for a facility. She said expanding Medicare consolidated billing to include high-cost drugs such as GLP-1s could be one way to reduce the burden on providers.
Care Plans and Facility Budgets
The growth in GLP-1 use affects more than a resident’s prescription list. Facilities may need to adjust nutrition assessments, weight monitoring and staff training, while accounting for medication costs that can shift to the provider during a stay. For residents, a monthly fee or a drug’s exclusion from a coverage arrangement may shape whether a treatment can continue after admission.
Jody O’Mara, chief nursing officer for Journey Skilled Nursing, told Skilled Nursing News that she sees potential value in the drugs, even as high prices remain a concern. She said GLP-1 use could change facility assessments, admissions decisions and quality-assurance programs. Those are operator views; the report does not establish that the drugs will produce the same benefits for every nursing home resident.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
Medicare Coverage Is Still Shifting
The coverage pathway described by McGill is a temporary bridge program under Medicare Part D. It can help eligible residents obtain certain drugs for weight loss, while GLP-1s prescribed for diabetes are covered under Part D, she said. Eligibility depends on clinical criteria, including BMI tiers and other chronic conditions, rather than applying uniformly to all residents seeking weight-loss treatment.
A more permanent coverage approach, called BALANCE, has been delayed without a future implementation date, according to the report. The bridge program has been extended through 2027. Separately, some drugs excluded from consolidated billing can be billed directly to Medicare Part B; McGill said including high-cost medications such as GLP-1s in consolidated billing would require congressional action.
““We see a lot of our new admissions coming in with GLP-1s.””
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Clinical Risks Vary
The report does not give a national estimate of how many nursing home residents use GLP-1s, or show whether the use reported by Venza Care reflects the broader sector. It also does not establish how often treatment improves health outcomes for older residents or how benefits compare with risks for people who are frail or have nutritional concerns.
Individual coverage depends on the prescription, eligibility and payer arrangements. The long-term status of the planned BALANCE program remains unclear, as does whether Congress will change consolidated billing. Clinically, nausea, vomiting, constipation and dehydration are among the adverse effects raised by Stenson; the report does not quantify how often these occur in nursing home residents.
Facilities Track Costs and Outcomes
The bridge program is scheduled to continue through 2027, but no implementation date has been announced for BALANCE. Until coverage rules change, nursing homes will need to review residents’ prescriptions and payer status, estimate costs where facilities may be responsible, and decide how their teams will monitor nutrition, hydration, weight and functional status.
Operators and care teams will also need to assess how GLP-1 use affects admissions and quality-assurance practices. A policy change to consolidated billing would require congressional action, McGill said. The timing and form of any such change have not been specified.
Key Questions
How common are GLP-1 medications among nursing home residents?
Venza Care’s Lisa Chubb said 30% to 40% of newly admitted residents at the company are on GLP-1s, with higher rates at facilities with more short-stay residents. The report does not provide a nationwide estimate.
Does Medicare help pay for GLP-1s prescribed for weight loss?
A Medicare Part D bridge program covers certain eligible prescriptions for weight loss, with a $50 monthly fee on top of Part D coverage, according to AAPACN’s Jessie McGill. The program covers Wegovy, Zepbound and Foundeo, she said, and eligibility is subject to criteria.
Who pays when a nursing home resident is covered by Medicare Part A?
McGill said the nursing home may be responsible for a resident’s GLP-1 medication cost under Medicare Part A. The exact cost implications depend on the prescription and coverage arrangement.
Why do GLP-1s require extra monitoring in nursing homes?
Care teams need to weigh potential benefits against weight loss, frailty and nutritional concerns. AAPACN’s Lauren Stenson also cited possible nausea, vomiting, constipation and dehydration. Facilities may use nutrition reviews and interdisciplinary monitoring to track residents.
Source: skillednursingnews.com
